

Public Assessment Report
Decentralised Procedure

NICABATE MINI 1.5MG COMPRESSED LOZENGES
NICABATE MINI 4MG COMPRESSED LOZENGES

UK/H/0287/0013-4/DC
UK Licence No: PL 00079/0612-3

BEECHAM GROUP PLC

LAY SUMMARY

Austria, Belgium, Germany, Italy, Luxembourg, the Netherlands, Poland, Portugal, Spain and the UK granted Beecham Group PLC Marketing Authorisations (licences) for the medicinal products Nicabate Mini 1.5 and 4mg Compressed Lozenges (PL 00079/0612-3; UK/H/0287/0013-4/DC) on 30th June 2008.

Nicabate Mini 1.5 and 4mg Compressed Lozenges contain nicotine (in the form of nicotine resinate), which is released slowly and absorbed through the lining of the mouth. The nicotine relieves some of the unpleasant symptoms that smokers often feel when they try to give up or when they are in situations where they cannot have a cigarette (such as feeling ill or irritable). The nicotine can reduce your cravings for a cigarette and reduce the urge to smoke.

These products are available on a General Sales Licence (GSL) and are indicated to help people stop smoking. This type of treatment is called Nicotine Replacement Therapy (NRT).

No new or unexpected safety concerns arose from these applications and it was, therefore, judged that the benefits of taking Nicabate Mini 1.5 and 4mg Compressed Lozenges outweigh the risks, hence Marketing Authorisations have been granted.

TABLE OF CONTENTS

Module 1: Information about initial procedure	Page 3
Module 2: Summary of Product Characteristics	Page 4
Module 3: Product Information Leaflets	Page 22
Module 4: Labelling	Page 24
Module 5: Scientific Discussion	Page 28
1 Introduction	
2 Quality aspects	
3 Non-clinical aspects	
4 Clinical aspects	
5 Overall conclusions	
Module 6	Steps taken after initial procedure

Module 1

Product Name	Nicabate Mini 1.5mg Compressed Lozenges Nicabate Mini 4mg Compressed Lozenges
Type of Application	Known Active Substance (Article 8.3)
Active Substance	Nicotine (as nicotine resinate)
Form	Compressed lozenge
Strength	1.5mg and 4mg
MA Holder	Beecham Group plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, T/A GlaxoSmithKline Consumer Healthcare, Brentford TW8 9GS, UK.
Reference Member State (RMS)	UK
CMS	Austria, Belgium, Germany, Spain, Italy, Luxembourg, the Netherlands, Poland, Portugal and Sweden
Procedure Number	UK/H/0287/0013-4/DC
Timetable	Final CMD(h) Day 60 Agreement – 28 th May 2008

Module 2

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Nicabate Mini 1.5 mg Compressed Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each lozenge contains 1.5 mg nicotine (as nicotine resinate).

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Compressed Lozenge (lozenge)

White to off white oval lozenge with convex surfaces; one surface bearing a debossed "L" logo.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Nicabate Minis are to be used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt (See Section 5.1). Permanent cessation of tobacco use is the eventual objective.

Nicabate Minis should preferably be used in conjunction with a behavioural support programme.

4.2 Posology and method of administration

Directions for use:

The strength of lozenge to be used will depend on the smoking habits of the individual.

Nicabate Minis 1.5 mg are suitable for smokers who smoke 20 cigarettes or less a day.

One lozenge should be placed in the mouth and allowed to dissolve. Periodically, the lozenge should be moved from one side of the mouth to the other, and repeated, until the lozenge is completely dissolved (approximately 10 minutes). The lozenge should not be chewed or swallowed whole.

Users should not eat or drink while a lozenge is in the mouth.

Behavioural therapy advice and support will normally improve the success rate.

Adults

Users should make every effort to stop smoking completely during treatment with Nicabate Minis.

Use the lozenges whenever there is an urge to smoke.

Sufficient lozenges should be used each day, usually 8-12, up to a maximum of 15.

Continue use for up to six weeks to break the habit of smoking, then gradually reduce lozenge use. When daily use is 1-2 lozenges, use should be stopped.

To help stay smoke free after treatment, users may take a lozenge in situations when they are strongly tempted to smoke.

Those who use lozenges beyond 9 months are recommended to seek additional help and advice from a healthcare professional.

Children and adolescents:

Nicabate Minis should only be used by adolescents (12-17 years inclusive) with advice from a healthcare professional.

Nicabate Minis are not recommended for use in children below the age of 12 due to a lack of data on safety and efficacy.

4.3 Contraindications

- people with hypersensitivity to nicotine or any of the excipients;
- children under the age of 12 years
- non-smokers.

4.4 Special warnings and precautions for use

The risks associated with the use of nicotine replacement therapy (NRT) are substantially outweighed in virtually all circumstances by the well established dangers of continued smoking.

Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal's angina, severe cardiac arrhythmias, uncontrolled hypertension or recent cerebrovascular accident should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, Nicabate Minis may be considered but as data on safety in this patient group are limited, initiation should only be under close medical supervision.

Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when NRT is initiated as catecholamines released by nicotine can affect carbohydrate metabolism.

Allergic reactions: susceptibility to angioedema and urticaria.

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

- *Renal and hepatic impairment:* Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.
- *Phaeochromocytoma and uncontrolled hyperthyroidism:* Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.
- *Gastrointestinal Disease:* Swallowed nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and oral NRT preparations should be used with caution in these conditions. Ulcerative stomatitis has been reported.

Danger in small children: Doses of nicotine tolerated by adult and adolescent smokers can produce severe toxicity in small children that may be fatal. Products containing nicotine should not be left where they may be misused, handled or ingested by children.

Stopping smoking: Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs catalysed by CYP 1A2 (and possibly by CYP 1A1). When a smoker stops this may result in a slower metabolism and a consequent rise in blood levels of such drugs.

Transferred dependence: Transferred dependence is rare and is both less harmful and easier to break than smoking dependence.

During a quit attempt users should not interchange Nicabate Minis with nicotine gums since pharmacokinetic data indicate a higher availability of nicotine from Nicabate Minis in comparison to the gum.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically relevant interactions between nicotine replacement therapy and other medicinal products have definitely been established, however nicotine may possibly enhance the haemodynamic effects of adenosine.

4.6 Pregnancy and lactation

Pregnancy

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both pregnant smoker and her baby. The earlier abstinence is achieved the better.

Ideally smoking cessation during pregnancy should be achieved without NRT. However for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt. The risk of using NRT to the fetus is lower than that expected with tobacco smoking, due to

lower maximal plasma nicotine concentration and no additional exposure to polycyclic hydrocarbons and carbon monoxide.

However, as nicotine passes to the fetus affecting breathing movements and has a dose dependent effect on placental/fetal circulation, the decision to use NRT should be made as early on in the pregnancy as possible. The aim should be to use NRT for only 2-3 months.

Intermittent dosing products may be preferable as these usually provide a lower daily dose of nicotine than patches. However patches may be preferred if the woman is suffering from nausea during pregnancy.

Lactation

Nicotine from smoking and NRT is found in breast milk. However the amount of nicotine the infant is exposed to from NRT is relatively small and less hazardous than the second-hand smoke they would otherwise be exposed to.

Ideally smoking cessation during lactation should be achieved without NRT. However for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt.

Using intermittent dose NRT preparations, compared with patches, may minimize the amount of nicotine in the breast milk as the time between administrations of NRT and feeding can be made as long as possible. Women should try to breastfeed just before they take the product.

4.7 Effects on ability to drive and use machines

There are no known effects of Nicabate Minis on the ability to drive and use machines. However, users of nicotine replacement products should be aware that smoking cessation can cause behavioural changes.

4.8 Undesirable effects

NRT can cause adverse reactions similar to those associated with nicotine administered in other ways, including smoking. These may be attributed to the pharmacological effects of nicotine, some of which are dose dependent. At recommended doses Nicabate Minis have not been found to cause any serious adverse effects. Excessive consumption of Nicabate Minis by those who have not been in the habit of inhaling tobacco smoke could possibly lead to nausea, faintness or headaches.

Certain symptoms which have been reported such as depression, irritability, anxiety, increased appetite and insomnia may be related to withdrawal symptoms associated with smoking cessation. Subjects quitting smoking by any means could expect to suffer from headache, dizziness, sleep disturbance, increased coughing or a cold.

Psychiatric disorders

Common ($\geq 1/100$ to $< 1/10$): irritability, anxiety, sleep disorders incl. abnormal dreams

Uncommon ($\geq 1/1000$ to $< 1/100$): nervousness, depression

Nervous system disorders:

Common ($\geq 1/100$ to $< 1/10$): dizziness, headaches

Cardiac Disorders

Uncommon ($\geq 1/1000$ to $< 1/100$): palpitations, heart rate increased

Respiratory, thoracic and mediastinal disorders

Common ($\geq 1/100$ to $< 1/10$): cough, sore throat

Gastrointestinal disorders

Very common ($\geq 1/10$): nausea, mouth/throat and tongue irritation

Common ($\geq 1/100$ to $< 1/10$): vomiting, diarrhoea, gastro-intestinal discomfort, flatulence, hiccups, heartburn, dyspepsia

Skin and Subcutaneous Tissue Disorders

Uncommon ($\geq 1/1000$ to $< 1/100$): rash

General Disorders and Administration Site Conditions

Uncommon ($\geq 1/1000$ to $< 1/100$): fatigue, malaise, chest pain

4.9 Overdose

Symptoms: The minimum lethal dose of nicotine in a non-tolerant man has been estimated to be 40 to 60 mg. Even small quantities of nicotine may be dangerous in children and may prove fatal. Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately. Symptoms of acute nicotine poisoning include nausea, salivation, abdominal pain, diarrhoea, sweating, headache, dizziness, disturbed hearing and marked weakness. In extreme cases, these symptoms may be followed by hypotension, rapid or weak or irregular pulse, breathing difficulties, prostration, circulatory collapse and terminal convulsions.

Management of an overdose: All nicotine intake should cease immediately and the patient should be treated symptomatically. Artificial respiration with oxygen should be instituted if necessary. Activated charcoal reduces the gastro-intestinal absorption of nicotine.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in nicotine dependence.
ATC Code: N07B A01

Nicotine is an agonist at nicotine receptors in the peripheral and central nervous system and has pronounced CNS and cardiovascular effects. When consumed in tobacco products, it has been shown to be addictive and abstinence is linked to craving and withdrawal symptoms. These craving and withdrawal symptoms include urge to smoke, depressed mood, insomnia, irritability, frustration or anger, anxiety, difficulty in concentrating, restlessness and increased appetite or weight gain. Cravings and other symptoms of nicotine withdrawal are at their most intense during the first few weeks of a quit attempt, diminishing thereafter. The lozenges replace some of the nicotine provided by tobacco and clinical studies measuring intensity of cravings and other withdrawal symptoms have been shown to alleviate these symptoms when they are at their most intense

5.2 Pharmacokinetic properties

Nicabate Minis dissolve completely in the oral cavity, and the entire amount of nicotine contained in the lozenge becomes available for buccal absorption or ingestion (swallowing). The complete dissolution of Nicabate Minis is typically achieved in 10 minutes. When dosed every hour, the steady state mean c_{max} and c_{min} concentrations are 18.4 and 15.0 ng/ml respectively.

As the plasma protein binding of nicotine is low (4.9%), the volume of distribution of nicotine is large (2.5 l/kg). The distribution of nicotine to tissue is pH dependent, with the highest concentrations of nicotine found in the brain, stomach, kidney and liver.

Nicotine is extensively metabolized to a number of metabolites, all of which are less active than the parent compound. The metabolism of nicotine primarily occurs in the liver, but also in the lung and kidney. Nicotine is metabolized primarily to cotinine but is also metabolized to nicotine N'-oxide. Cotinine has a half-life of 15-20 hours and its blood levels are 10 times higher than nicotine. Cotinine is further oxidized to trans-3'-hydroxycotinine, which is the most abundant metabolite of nicotine in the urine. Both nicotine and cotinine undergo glucuronidation.

The elimination half-life of nicotine is approximately 2 hours (range 1 - 4 hours). Total clearance for nicotine ranges from approximately 62 to 89 l/hr. Non-renal clearance for nicotine is estimated to be about 75% of total clearance. Nicotine and its metabolites are excreted almost exclusively in the urine. The renal excretion of unchanged nicotine is highly dependent on urinary pH, with greater excretion occurring at acidic pH.

5.3 Preclinical safety data

The general toxicity of nicotine is well known and taken into account in the recommended posology. Nicotine was not mutagenic in appropriate assays. The results of carcinogenicity assays did not provide any clear evidence of a tumorigenic effect of nicotine. In studies in pregnant animals, nicotine showed maternal toxicity, and consequential mild fetal toxicity. Additional effects included pre- and postnatal growth retardation and delays and changes in postnatal CNS development.

Effects were only noted following exposure to nicotine at levels in excess of those which will result from recommended use Nicabate Minis. Effects on fertility have not been established.

Comparison of the systemic exposure necessary to elicit these adverse responses from preclinical test systems with that associated with the recommended use of Nicabate Minis indicate that the potential risk is low and outweighed by the demonstrable benefit of nicotine therapy in smoking cessation. However, Nicabate Minis should only be used by pregnant women on medical advice if other forms of treatment have failed.

6 PHARMACEUTICAL PARTICULARS**6.1 List of excipients**

Mannitol (E421)
Sodium alginate
Xanthan gum
Potassium bicarbonate
Calcium polycarbophil
Sodium carbonate anhydrous
Acesulfame potassium
Taste Masking Flavour 031431
Peppermint Flavour 022173
Menthol Flavour 020184
Magnesium Stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C. Store in the original package in order to protect the product from moisture.

6.5 Nature and contents of container

Child resistant polypropylene tablet container/cap incorporating a molecular sieve desiccant (sodium aluminosilicate) and containing 20 lozenges

Packs may contain 1 or 3 tablet containers.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

Beecham Group plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
T/A GlaxoSmithKline Consumer Healthcare
Brentford TW8 9GS, UK.

- 8** **MARKETING AUTHORISATION NUMBER(S)**
PL 00079/0612
- 9** **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**
27/06/2008
- 10** **DATE OF REVISION OF THE TEXT**
27/06/2008

1 NAME OF THE MEDICINAL PRODUCT

Nicabate Mini 4 mg Compressed Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each lozenge contains 4 mg nicotine (as nicotine resinolate).
For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Compressed Lozenge (lozenge)

White to off white oval lozenge with convex surfaces; one surface bearing a debossed "F" logo.

4 CLINICAL PARTICULARS**4.1 Therapeutic indications**

Nicabate Minis are to be used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt (See Section 5.1). Permanent cessation of tobacco use is the eventual objective.

Nicabate Minis should preferably be used in conjunction with a behavioural support programme.

4.2 Posology and method of administration

Directions for use:

The strength of lozenge to be used will depend on the smoking habits of the individual.

Nicabate Minis 4 mg are suitable for smokers who smoke more than 20 cigarettes or less a day.

One lozenge should be placed in the mouth and allowed to dissolve. Periodically, the lozenge should be moved from one side of the mouth to the other, and repeated, until the lozenge is completely dissolved (approximately 10 minutes). The lozenge should not be chewed or swallowed whole.

Users should not eat or drink while a lozenge is in the mouth.

Behavioural therapy advice and support will normally improve the success rate.

Adults

Users should make every effort to stop smoking completely during treatment with Nicabate Minis.

Use the lozenges whenever there is an urge to smoke.

Sufficient lozenges should be used each day, usually 8-12, up to a maximum of 15.

Continue use for up to six weeks to break the habit of smoking, then gradually reduce lozenge use. When daily use is 1-2 lozenges, use should be stopped.

To help stay smoke free after treatment, users may take a lozenge in situations when they are strongly tempted to smoke.

Those who use lozenges beyond 9 months are recommended to seek additional help and advice from a healthcare professional.

Children and adolescents:

Nicabate Minis should only be used by adolescents (12-17 years inclusive) with advice from a healthcare professional.

Nicabate Minis are not recommended for use in children below the age of 12 due to a lack of data on safety and efficacy.

4.3 Contraindications

- people with hypersensitivity to nicotine or any of the excipients;
- children under the age of 12 years
- non-smokers.

4.4 Special warnings and precautions for use

The risks associated with the use of nicotine replacement therapy (NRT) are substantially outweighed in virtually all circumstances by the well established dangers of continued smoking.

Dependent smokers with a recent myocardial infarction, unstable or worsening angina including Prinzmetal's angina, severe cardiac arrhythmias, uncontrolled hypertension or recent cerebrovascular accident should be encouraged to stop smoking with non-pharmacological interventions (such as counselling). If this fails, Nicabate Minis may be considered but as data on safety in this patient group are limited, initiation should only be under close medical supervision.

Diabetes Mellitus. Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when NRT is initiated as catecholamines released by nicotine can affect carbohydrate metabolism.

Allergic reactions: susceptibility to angioedema and urticaria.

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

- *Renal and hepatic impairment:* Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.
- *Phaeochromocytoma and uncontrolled hyperthyroidism:* Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.
- *Gastrointestinal Disease:* Swallowed nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and oral NRT preparations should be used with caution in these conditions. Ulcerative stomatitis has been reported.

Danger in small children: Doses of nicotine tolerated by adult and adolescent smokers can produce severe toxicity in small children that may be fatal. Products containing nicotine should not be left where they may be misused, handled or ingested by children.

Stopping smoking: Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs catalysed by CYP 1A2 (and possibly by CYP 1A1). When a smoker stops this may result in a slower metabolism and a consequent rise in blood levels of such drugs.

Transferred dependence: Transferred dependence is rare and is both less harmful and easier to break than smoking dependence.

During a quit attempt users should not interchange Nicabate Minis with nicotine gums since pharmacokinetic data indicate a higher availability of nicotine from Nicabate Minis in comparison to the gum.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically relevant interactions between nicotine replacement therapy and other medicinal products have definitely been established, however nicotine may possibly enhance the haemodynamic effects of adenosine.

4.6 Pregnancy and lactation

Pregnancy

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both pregnant smoker and her baby. The earlier abstinence is achieved the better.

Ideally smoking cessation during pregnancy should be achieved without NRT. However for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt. The risk of using NRT to the fetus is lower than that expected with tobacco smoking, due to lower maximal plasma nicotine concentration and no additional exposure to polycyclic hydrocarbons and carbon monoxide.

However, as nicotine passes to the fetus affecting breathing movements and has a dose dependent effect on placental/fetal circulation, the decision to use NRT should be made as early on in the pregnancy as possible. The aim should be to use NRT for only 2-3 months.

Intermittent dosing products may be preferable as these usually provide a lower daily dose of nicotine than patches. However patches may be preferred if the woman is suffering from nausea during pregnancy.

Lactation

Nicotine from smoking and NRT is found in breast milk. However the amount of nicotine the infant is exposed to from NRT is relatively small and less hazardous than the second-hand smoke they would otherwise be exposed to.

Ideally smoking cessation during lactation should be achieved without NRT. However for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt.

Using intermittent dose NRT preparations, compared with patches, may minimize the amount of nicotine in the breast milk as the time between administrations of NRT and feeding can be made as long as possible. Women should try to breastfeed just before they take the product.

4.7 Effects on ability to drive and use machines

There are no known effects of Nicabate Minis on the ability to drive and use machines. However, users of nicotine replacement products should be aware that smoking cessation can cause behavioural changes.

4.8 Undesirable effects

NRT can cause adverse reactions similar to those associated with nicotine administered in other ways, including smoking. These may be attributed to the pharmacological effects of nicotine, some of which are dose dependent. At recommended doses Nicabate Minis have not been found to cause any serious adverse effects. Excessive consumption of Nicabate Minis by those who have not been in the habit of inhaling tobacco smoke could possibly lead to nausea, faintness or headaches.

Certain symptoms which have been reported such as depression, irritability, anxiety, increased appetite and insomnia may be related to withdrawal symptoms associated with smoking cessation. Subjects quitting smoking by any means could expect to suffer from headache, dizziness, sleep disturbance, increased coughing or a cold.

Psychiatric disorders

Common ($\geq 1/100$ to $< 1/10$): irritability, anxiety, sleep disorders incl. abnormal dreams

Uncommon ($\geq 1/1000$ to $< 1/100$): nervousness, depression

Nervous system disorders:

Common ($\geq 1/100$ to $< 1/10$): dizziness, headaches

Cardiac Disorders

Uncommon ($\geq 1/1000$ to $< 1/100$): palpitations, heart rate increased

Respiratory, thoracic and mediastinal disorders

Common ($\geq 1/100$ to $< 1/10$): cough, sore throat

Gastrointestinal disorders

Very common ($\geq 1/10$): nausea, mouth/throat and tongue irritation

Common ($\geq 1/100$ to $< 1/10$): vomiting, diarrhoea, gastro-intestinal discomfort, flatulence, hiccups, heartburn, dyspepsia

Skin and Subcutaneous Tissue Disorders

Uncommon ($\geq 1/1000$ to $< 1/100$): rash

General Disorders and Administration Site Conditions

Uncommon ($\geq 1/1000$ to $< 1/100$): fatigue, malaise, chest pain

4.9 Overdose

Symptoms: The minimum lethal dose of nicotine in a non-tolerant man has been estimated to be 40 to 60 mg. Even small quantities of nicotine may be dangerous in children and may prove fatal. Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately. Symptoms of acute nicotine poisoning include nausea, salivation, abdominal pain, diarrhoea, sweating, headache, dizziness, disturbed hearing and marked weakness. In extreme cases, these symptoms may be followed by hypotension, rapid or weak or irregular pulse, breathing difficulties, prostration, circulatory collapse and terminal convulsions.

Management of an overdose: All nicotine intake should cease immediately and the patient should be treated symptomatically. Artificial respiration with oxygen should be instituted if necessary. Activated charcoal reduces the gastro-intestinal absorption of nicotine.

5 PHARMACOLOGICAL PROPERTIES**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Drugs used in nicotine dependence.

ATC Code: N07B A01

Nicotine is an agonist at nicotine receptors in the peripheral and central nervous system and has pronounced CNS and cardiovascular effects. When consumed in tobacco products, it has been shown to be addictive and abstinence is linked to craving and withdrawal symptoms. These craving and withdrawal symptoms include urge to smoke, depressed mood, insomnia, irritability, frustration or anger, anxiety, difficulty in concentrating, restlessness and increased appetite or weight gain. Cravings and other symptoms of nicotine withdrawal are at their most intense during the first few weeks of a quit attempt, diminishing thereafter. The lozenges replace some of the nicotine provided by tobacco and clinical studies measuring intensity of cravings and other withdrawal symptoms have been shown to alleviate these symptoms when they are at their most intense

5.2 Pharmacokinetic properties

Nicabate Minis dissolve completely in the oral cavity, and the entire amount of nicotine contained in the lozenge becomes available for buccal absorption or ingestion (swallowing). The complete dissolution of Nicabate Minis is typically achieved in 10 minutes. The mean peak plasma concentration of nicotine achieved after single 4 mg dose is approximately 9.1 ng/ml.

As the plasma protein binding of nicotine is low (4.9%), the volume of distribution of nicotine is large (2.5 l/kg). The distribution of nicotine to tissue is pH dependent, with the highest concentrations of nicotine found in the brain, stomach, kidney and liver.

Nicotine is extensively metabolized to a number of metabolites, all of which are less active than the parent compound. The metabolism of nicotine primarily occurs in the liver, but also in the lung and kidney. Nicotine is metabolized primarily to cotinine but is also metabolized to nicotine N'-oxide. Cotinine has a half-life of 15-20 hours and its blood levels are 10 times higher than nicotine. Cotinine is further oxidized to trans-3'-hydroxycotinine, which is the most abundant metabolite of nicotine in the urine. Both nicotine and cotinine undergo glucuronidation.

The elimination half-life of nicotine is approximately 2 hours (range 1 - 4 hours). Total clearance for nicotine ranges from approximately 62 to 89 l/hr. Non-renal clearance for nicotine is estimated to be about 75% of total clearance. Nicotine and its metabolites are excreted almost exclusively in the urine. The renal excretion of unchanged nicotine is highly dependent on urinary pH, with greater excretion occurring at acidic pH.

5.3 Preclinical safety data

The general toxicity of nicotine is well known and taken into account in the recommended posology. Nicotine was not mutagenic in appropriate assays. The results of carcinogenicity assays did not provide any clear evidence of a tumorigenic effect of nicotine. In studies in pregnant animals, nicotine showed maternal toxicity, and consequential mild fetal toxicity. Additional effects included pre- and postnatal growth retardation and delays and changes in postnatal CNS development.

Effects were only noted following exposure to nicotine at levels in excess of those which will result from recommended use Nicabate Minis. Effects on fertility have not been established.

Comparison of the systemic exposure necessary to elicit these adverse responses from preclinical test systems with that associated with the recommended use of Nicabate Minis indicate that the potential risk is low and outweighed by the demonstrable benefit of nicotine therapy in smoking cessation. However, Nicabate Minis should only be used by pregnant women on medical advice if other forms of treatment have failed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol (E421)
Sodium alginate
Xanthan gum
Potassium bicarbonate
Calcium polycarbophil
Sodium carbonate anhydrous
Acesulfame potassium
Taste Masking Flavour 031431
Peppermint Flavour 022173
Menthol Flavour 020184
Magnesium Stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C. Store in the original package in order to protect the product from moisture.

6.5 Nature and contents of container

Child resistant polypropylene tablet container/cap incorporating a molecular sieve desiccant (sodium aluminosilicate) and containing 20 lozenges

Packs may contain 1 or 3 tablet containers.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

Beecham Group plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
T/A GlaxoSmithKline Consumer Healthcare
Brentford TW8 9GS, UK.

8 MARKETING AUTHORISATION NUMBER(S)

PL 00079/0613

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27/06/2008

10 DATE OF REVISION OF THE TEXT

27/06/2008

Module 3

Patient Information Leaflet

Please note that, as the products are not currently being marketed in the UK, only the approved text for the Patient Information Leaflet is being presented. The Marketing Authorisation Holder has agreed to submit the mock-up of the Patient Information Leaflet to the MHRA for approval before marketing the products.

PACKAGE LEAFLET : INFORMATION FOR THE USER

Nicabate Mini 1.5 mg Lozenges Nicotine

Please read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you still need to use Nicabate Minis carefully to get the best results from them.

- Keep this leaflet. You may need to read it again.
- Ask a healthcare professional e.g. doctor, nurse, smoking cessation adviser or pharmacist if you need more information or advice.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell a healthcare professional.
- Throughout this leaflet Nicabate Mini 1.5 mg Lozenges are referred to as Nicabate Minis.

In this leaflet:

1. What Nicabate Minis are and what they are used for
2. Before you take Nicabate Minis
3. How to use Nicabate Minis
4. Possible side effects
5. How to store Nicabate Minis
6. Further information

1. What Nicabate Minis are and what they are used for

Nicabate Minis are used to help people stop smoking. This type of treatment is called Nicotine Replacement Therapy or NRT.

It is the nicotine in cigarettes that can make you physically addicted to them.

- Nicabate Minis help you to give up smoking by replacing some of the nicotine you get from cigarettes.
- This nicotine relieves some of the unpleasant symptoms that smokers may have when they try to give up. These include feeling ill or irritable.
- The nicotine can also relieve your cravings for a cigarette and help you to resist the urge to smoke.

Nicabate Minis do not have the health dangers of tobacco. This is because they do not contain the tar, carbon monoxide or other toxins in cigarette smoke. Some people worry that after stopping smoking, they may become dependent on nicotine lozenges instead. This is very rare, and if it did happen, it is less harmful than continuing to smoke. It also an easier habit to break.

Your chances of stopping smoking will be improved if you take part in a support programme. These “stop smoking programmes” are known as behavioural support. For information on stop smoking programmes please talk to a healthcare professional.

2. Before you take Nicabate Minis

Do not use Nicabate Minis if:

- you are allergic (hypersensitive) to nicotine or any of the other ingredients in the lozenge (See Section 6: Further information)
- you are a non-smoker or under the age of 12 years.

There are no health benefits to smoking. It is always better to give up smoking. Using Nicotine Replacement Therapy (NRT), like Nicabate Minis, can help. In general, any possible side effects associated with NRT are far outweighed by the well known dangers of continuing to smoke.

Take special care with Nicabate Minis:

- **If you have had a recent heart attack or stroke, or you suffer from severe heart rhythm problems, unstable or worsening angina (chest pain) or resting angina** you should try to quit smoking without using any NRT products unless your doctor tells you to use them.
- **If you have diabetes** you should monitor your blood sugar levels more often than usual when you start using Nicabate Minis. Your insulin or medicine requirements may change.
- **If you have ever had allergic reactions** that involve swelling of the lips, face and throat (angioedema) or itchy skin rash (urticaria). Using NRT can sometimes trigger this type of reaction.
- **If you have children under 12 years** as the levels of nicotine in Nicotine Replacement Therapy (NRT) are not suitable for children under 12. The effects of nicotine affect children more than adults. It could cause severe poisoning in children which can cause death.
- Do not interchange between Nicabate Minis and nicotine gums during any attempt to quit smoking.

If you are pregnant or breast feeding it is best if you can give up smoking without the use of NRT. However, it is better to stop smoking using NRT than to continue smoking. (See the section on pregnancy or breastfeeding below for more information.)

Get help and advice from a healthcare professional if you have:

- **Serious liver or kidney problems** because you may be more likely to get side effects.
- **Uncontrolled overactive thyroid gland or phaeochromocytoma** (a tumour of the adrenal gland that can affect blood pressure) - your doctor will have told you this - because nicotine may make your symptoms worse.
- **Stomach or duodenal ulcers or an inflamed oesophagus or gullet** (the passage between the mouth and stomach) because swallowing nicotine can make your symptoms worse. It may also cause mouth ulcers. If your symptoms do get worse you should talk to your doctor. You might want to use a non-oral form of NRT instead, such as patches.

Taking other medicines

Please tell your healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription

Pregnancy and breast feeding

Smoking during **pregnancy** has risks for the baby. These include poor growth before birth, premature birth or stillbirth. Stopping smoking is the best way to improve both your health and that of your baby. The earlier you stop smoking the better.

Ideally, if you are pregnant, you should stop smoking without using NRT. However, if you have tried and this has not worked, NRT may be recommended by a healthcare professional to help you stop smoking. This is because it is better for your developing baby than if you carry on smoking. The decision to use NRT should be made as early on as possible in your pregnancy. You should aim to use it for only 2-3 months. Remember, the most important thing is to stop smoking. Products such as lozenges may be preferable to nicotine patches. This is because with lozenges, you do not get the nicotine all the time. However, patches may be preferred if you have nausea or sickness.

If you are **breast feeding** tobacco smoke causes breathing difficulties and other problems in babies and children. Ideally you should stop smoking without using NRT. However if you have tried and this has not worked, NRT may be recommended by a healthcare professional. If you do

use NRT to help you quit, the amount of nicotine your baby may get is small. It is much less harmful than breathing in second hand smoke. It is best to use NRT products that are taken at certain times of the day (such as gum or lozenge, rather than patches). It is also better to breast feed just before you take the product. This helps your baby to get the smallest amount of nicotine possible.

Driving and using machines

Stopping smoking can result in difficulties concentrating and increased irritability.

3. How to use Nicabate Minis

Always use Nicabate Minis exactly as stated in this package leaflet. You should check with your healthcare professional if you are not sure.

You should use Nicabate Minis by putting one lozenge in your mouth and from time to time move it from one side of your mouth to the other, until it is completely dissolved. This should take around 10 minutes. Do not chew the lozenge or swallow it whole. Do not use more than 15 lozenges a day. If you feel the need to use Nicabate Minis for longer than 9 months in total, you should ask a healthcare professional for advice.

Adults (18 years and over)

- Start by using 8 to 12 lozenges a day. Suck a lozenge whenever you have an urge to smoke.
- Use the lozenges like this for up to 6 weeks, then gradually cut down the number of lozenges you use a day.
- Once you are using only 1 or 2 lozenges a day, stop using them altogether.

After you have given up you may sometimes feel a sudden craving for a cigarette. You can use a lozenge again if this happens.

Young people (12-17 years inclusive)

You should only use Nicabate Minis following advice from a healthcare professional.

Do not exceed the stated dose. Follow the instructions carefully and do not use more than 15 lozenges in one day (24 hours).

Children under 12 years of age should not use Nicabate Minis.

This product is for oromucosal use. That means that the nicotine in the tablets is released slowly into the mouth from where it is absorbed into the body.

If you are tempted to start smoking again

If you are:

- worried that you may start smoking again
- finding it difficult to stop using the lozenges completely

talk to a healthcare professional.

If you do start to smoke again, they can advise you on how to get the best results from further courses of Nicotine Replacement Therapy (NRT).

If you take more Nicabate Minis than you should

If you use too many Nicabate Minis you may start to feel sick, dizzy and unwell. Stop using the lozenges and get advice straightaway from a doctor or hospital casualty department. If possible, show them the packet or this leaflet.

The lozenges are not suitable for children under 12 or non-smokers. If the lozenges are used by children or non-smokers they may show signs of nicotine overdose. These include headache, sickness, stomach pains and diarrhoea. If a child has used or eaten any of the lozenges, contact your doctor or nearest hospital casualty department straightaway. If possible show them the packet or this leaflet.

If you have any further questions on the use of this product, ask your healthcare professional

4. Possible Side Effects

Like all medicines Nicabate Minis can cause side effects, although not everybody gets them. At the recommended doses Nicabate Minis have not been found to cause any serious side effects.

Stopping smoking itself can cause symptoms such as dizziness, headache, sleep disturbance, cough and cold-like symptoms. Symptoms such as depression, irritability, anxiety, restlessness, increased appetite and insomnia may also be related to withdrawal symptoms associated with giving up smoking.

Other Side effects are listed below - they are group based on the likelihood with which they can occur:

Very common (affects *more than* 1 in 10 people)

- The lozenges may cause your mouth or tongue to be slightly sore or irritated. You may also feel sick.

Common (affects *between* 1 in 10 and 1 in 100 people)

- Sore throat
- Being sick
- Stomach discomfort
- Diarrhoea
- Indigestion/heartburn
- Flatulence
- Hiccups

Less common side effects (affects *between* 1 in 100 and 1 in 1000 people)

- Nervousness
- Depression
- Palpitations (feeling your heart beat)
- Increased heart beat
- Chest pain
- Rash
- Tiredness and generally feeling unwell

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell a healthcare professional.

5. How to store Nicabate Minis

- **Keep all medicines out of the reach and sight of children.**
- Do not use the lozenges after the expiry date stated on the container and outer packaging. The expiry date refers to the last day of the month.
- Do not store above 30°C.
- Store in the original container in order to protect from moisture.
- Do not use the container for anything else due to possible fine coating of tablet dust in the container.
- Dispose of the container responsibly. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Further Information**What Nicabate Minis contain**

The active substance is nicotine. Each lozenge contains 1.5 mg (in the form of a resin complex called nicotine resinate). **The other ingredients** are mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, calcium polycarbophil, sodium carbonate anhydrous, acesulfame potassium, taste masking flavour, peppermint flavour, menthol flavour, magnesium stearate.

What Nicabate Minis look like and contents of the pack

White to off-white oval compressed lozenges (lozenges) with convex surfaces.

The 1.5 mg lozenge has an "L" on one side.

Each container contains 20 lozenges. Packs may contain one or three containers.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

To be completed nationally.

The manufacturer of Nicabate Minis is Catalent UK Packaging Ltd., Sedge Close, Great Oakley, Corby, Northamptonshire, NN18 8HS. UK.

This medicinal product is authorised in the Member States of the EEA under the following names:

This information to be included at the end of the procedure once all MS names have been agreed.

This leaflet was last approved in {MM/YYYY}.

PACKAGE LEAFLET : INFORMATION FOR THE USER**Nicabate Mini 4 mg Lozenges
Nicotine**

Please read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you still need to use Nicabate Minis carefully to get the best results from them.

- Keep this leaflet. You may need to read it again.
- Ask a healthcare professional e.g. doctor, nurse, smoking cessation adviser or pharmacist if you need more information or advice.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell a healthcare professional.
- Throughout this leaflet Nicabate Mini 4 mg Lozenges are referred to as Nicabate Minis.

In this leaflet:

1. What Nicabate Minis are and what they are used for
2. Before you take Nicabate Minis
3. How to use Nicabate Minis
4. Possible side effects
5. How to store Nicabate Minis
6. Further information

1. What Nicabate Minis are and what they are used for

Nicabate Minis are used to help people stop smoking. This type of treatment is called Nicotine Replacement Therapy or NRT.

It is the nicotine in cigarettes that can make you physically addicted to them.

- Nicabate Minis help you to give up smoking by replacing some of the nicotine you get from cigarettes.
- This nicotine relieves some of the unpleasant symptoms that smokers may have when they try to give up. These include feeling ill or irritable.
- The nicotine can also relieve your cravings for a cigarette and help you to resist the urge to smoke.

Nicabate Minis do not have the health dangers of tobacco. This is because they do not contain the tar, carbon monoxide or other toxins in cigarette smoke. Some people worry that after stopping smoking, they may become dependent on nicotine lozenges instead. This is very rare, and if it did happen, it is less harmful than continuing to smoke. It also an easier habit to break.

Your chances of stopping smoking will be improved if you take part in a support programme. These "stop smoking programmes" are known as behavioural support. For information on stop smoking programmes please talk to a healthcare professional.

2. Before you take Nicabate Minis

Do not use Nicabate Minis if:

- you are allergic (hypersensitive) to nicotine or any of the other ingredients in the lozenge (See Section 6: Further information)
- you are a non-smoker or under the age of 12 years.

There are no health benefits to smoking. It is always better to give up smoking. Using Nicotine Replacement Therapy (NRT), like Nicabate Minis, can help. In general, any possible side effects associated with NRT are far outweighed by the well known dangers of continuing to smoke.

Take special care with Nicabate Minis:

- **If you have had a recent heart attack or stroke, or you suffer from severe heart rhythm problems, unstable or worsening angina (chest pain) or resting angina** you should try to quit smoking without using any NRT products unless your doctor tells you to use them.
- **If you have diabetes** you should monitor your blood sugar levels more often than usual when you start using Nicabate Minis. Your insulin or medicine requirements may change.
- **If you have ever had allergic reactions** that involve swelling of the lips, face and throat (angioedema) or itchy skin rash (urticaria). Using NRT can sometimes trigger this type of reaction.
- **If you have children under 12 years** as the levels of nicotine in Nicotine Replacement Therapy (NRT) are not suitable for children under 12. The effects of nicotine affect children more than adults. It could cause severe poisoning in children which can cause death.
- Do not interchange between Nicabate Minis and nicotine gums during any attempt to quit smoking.

If you are pregnant or breast feeding it is best if you can give up smoking without the use of NRT. However, it is better to stop smoking using NRT than to continue smoking. (See the section on pregnancy or breastfeeding below for more information.)

Get help and advice from a healthcare professional if you have:

- **Serious liver or kidney problems** because you may be more likely to get side effects.
- **Uncontrolled overactive thyroid gland or pheochromocytoma** (a tumour of the adrenal gland that can affect blood pressure) - your doctor will have told you this - because nicotine may make your symptoms worse.
- **Stomach or duodenal ulcers or an inflamed oesophagus or gullet** (the passage between the mouth and stomach) because swallowing nicotine can make your symptoms worse. It may also cause mouth ulcers. If your symptoms do get worse you should talk to your doctor. You might want to use a non-oral form of NRT instead, such as patches.

Taking other medicines

Please tell your healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription

Pregnancy and breast feeding

Smoking during **pregnancy** has risks for the baby. These include poor growth before birth, premature birth or stillbirth. Stopping smoking is the best way to improve both your health and that of your baby. The earlier you stop smoking the better.

Ideally, if you are pregnant, you should stop smoking without using NRT. However, if you have tried and this has not worked, NRT may be recommended by a healthcare professional to help you stop smoking. This is because it is better for your developing baby than if you carry on smoking. The decision to use NRT should be made as early on as possible in your pregnancy. You should aim to use it for only 2-3 months. Remember, the most important thing is to stop smoking. Products such as lozenges may be preferable to nicotine patches. This is because with lozenges, you do not get the nicotine all the time. However, patches may be preferred if you have nausea or sickness.

If you are **breast feeding** tobacco smoke causes breathing difficulties and other problems in babies and children. Ideally you should stop smoking without using NRT. However if you have tried and this has not worked, NRT may be recommended by a healthcare professional. If you do

use NRT to help you quit, the amount of nicotine your baby may get is small. It is much less harmful than breathing in second hand smoke. It is best to use NRT products that are taken at certain times of the day (such as gum or lozenge, rather than patches). It is also better to breast feed just before you take the product. This helps your baby to get the smallest amount of nicotine possible.

Driving and using machines

Stopping smoking can result in difficulties concentrating and increased irritability.

3. How to use Nicabate Minis

Always use Nicabate Minis exactly as stated in this package leaflet. You should check with your healthcare professional if you are not sure.

You should use Nicabate Minis by putting one lozenge in your mouth and from time to time move it from one side of your mouth to the other, until it is completely dissolved. This should take around 10 minutes. Do not chew the lozenge or swallow it whole. Do not use more than 15 lozenges a day. If you feel the need to use Nicabate Minis for longer than 9 months in total, you should ask a healthcare professional for advice.

Adults (18 years and over)

- Start by using 8 to 12 lozenges a day. Suck a lozenge whenever you have an urge to smoke.
- Use the lozenges like this for up to 6 weeks, then gradually cut down the number of lozenges you use a day.
- Once you are using only 1 or 2 lozenges a day, stop using them altogether.

After you have given up you may sometimes feel a sudden craving for a cigarette. You can use a lozenge again if this happens.

Young people (12-17 years inclusive)

You should only use Nicabate Minis following advice from a healthcare professional.

Do not exceed the stated dose. Follow the instructions carefully and do not use more than 15 lozenges in one day (24 hours).

Children under 12 years of age should not use Nicabate Minis.

This product is for oromucosal use. That means that the nicotine in the tablets is released slowly into the mouth from where it is absorbed into the body.

If you are tempted to start smoking again

If you are:

- worried that you may start smoking again
 - finding it difficult to stop using the lozenges completely
- talk to a healthcare professional.

If you do start to smoke again, they can advise you on how to get the best results from further courses of Nicotine Replacement Therapy (NRT).

If you take more Nicabate Minis than you should

If you use too many Nicabate Minis you may start to feel sick, dizzy and unwell. Stop using the lozenges and get advice straightaway from a doctor or hospital casualty department. If possible, show them the packet or this leaflet.

The lozenges are not suitable for children under 12 or non-smokers. If the lozenges are used by children or non-smokers they may show signs of nicotine overdose. These include headache, sickness, stomach pains and diarrhoea. If a child has used or eaten any of the lozenges, contact your doctor or nearest hospital casualty department straightaway. If possible show them the packet or this leaflet.

If you have any further questions on the use of this product, ask your healthcare professional

4. Possible Side Effects

Like all medicines Nicabate Minis can cause side effects, although not everybody gets them. At the recommended doses Nicabate Minis have not been found to cause any serious side effects.

Stopping smoking itself can cause symptoms such as dizziness, headache, sleep disturbance, cough and cold-like symptoms. Symptoms such as depression, irritability, anxiety, restlessness, increased appetite and insomnia may also be related to withdrawal symptoms associated with giving up smoking.

Other Side effects are listed below - they are group based on the likelihood with which they can occur:

Very common (affects *more than* 1 in 10 people)

- The lozenges may cause your mouth or tongue to be slightly sore or irritated. You may also feel sick.

Common (affects *between* 1 in 10 and 1 in 100 people)

- Sore throat
- Being sick
- Stomach discomfort
- Diarrhoea
- Indigestion/heartburn
- Flatulence
- Hiccups

Less common side effects (affects *between* 1 in 100 and 1 in 1000 people)

- Nervousness
- Depression
- Palpitations (feeling your heart beat)
- Increased heart beat
- Chest pain
- Rash
- Tiredness and generally feeling unwell

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell a healthcare professional.

5. How to store Nicabate Minis

- **Keep all medicines out of the reach and sight of children.**
- Do not use the lozenges after the expiry date stated on the container and outer packaging. The expiry date refers to the last day of the month.
- Do not store above 30°C.
- Store in the original container in order to protect from moisture.
- Do not use the container for anything else due to possible fine coating of tablet dust in the container.
- Dispose of the container responsibly. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Further Information**What Nicabate Minis contain**

The active substance is nicotine. Each lozenge contains 4 mg (in the form of a resin complex called nicotine resinate). **The other ingredients** are mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, calcium polycarbophil, sodium carbonate anhydrous, acesulfame potassium, taste masking flavour, peppermint flavour, menthol flavour, magnesium stearate.

What Nicabate Minis look like and contents of the pack

White to off-white oval compressed lozenges (lozenges) with convex surfaces.

The 4 mg lozenge has an “F” on one side.

Each container contains 20 lozenges. Packs may contain one or three containers

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

To be completed nationally.

The manufacturer of Nicabate Minis is Catalent UK Packaging Ltd., Sedge Close, Great Oakley, Corby, Northamptonshire, NN18 8HS. UK.

This medicinal product is authorised in the Member States of the EEA under the following names:

This information to be included at the end of the procedure once all MS names have been agreed.

This leaflet was last approved in {MM/YYYY}.

Module 4

Labelling

Please note that, as the products are not currently being marketed in the UK, only the approved text for the labelling is being presented. The Marketing Authorisation Holder has agreed to submit mock-ups of the labelling to the MHRA for approval before marketing the products.

Particulars to appear on the Outer Packaging

1. Name of the medicinal product

Nicabate Mini 1.5 mg Lozenges

Nicotine

2. Statement of active substance

Each lozenge contains 1.5 mg nicotine (as nicotine resinate)

3. List of excipients

Mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, polycarbophil calcium, sodium carbonate, acesulfame potassium, magnesium stearate and flavours.

4. Pharmaceutical form and contents

1 x 20 compressed lozenges

60 (3 x 20) compressed lozenges

5. Method and route of administration

For oromucosal use. Put one Nicabate Mini in your mouth and allow to dissolve fully. For full instructions please read the enclosed leaflet carefully.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach and sight of children.

7. Other special warnings, if necessary

8. Expiry date

EXP:

9. Special storage conditions

Do not store above 30°C. Store in the original container in order to protect the product from moisture.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal product, if appropriate

11. Name and address of marketing authorisation holder

To be completed nationally.

12. Marketing authorisation number

To be completed nationally.

13. Batch number

Lot

14. General classification for supply

To be completed nationally.

15. Instructions for use

Stop smoking aid

Nicabate Minis are used to help people stop smoking.

FOR THOSE WHO SMOKE 20 CIGARETTES OR LESS PER DAY

HOW TO USE

Do not use more than 15 Nicabate Minis a day.

Young people (12-17 years inclusive) should only use Nicabate Minis following advice from a healthcare professional.

DO NOT USE

- if you are allergic to any of the ingredients listed.
- if you are a non-smoker or under the age of 12 years.

CONSULT A HEALTHCARE PROFESSIONAL

- if you have or have recently had heart problems
- if you have serious liver or kidney disease; uncontrolled overactive thyroid gland or phaeochromocytoma; stomach ulcers or other problems with your stomach or throat.
- before use if you are pregnant or breast feeding.

16. Information in Braille

To be completed nationally.

Particulars to appear on the Outer Packaging**1. Name of the medicinal product**

Nicabate Mini 1.5 mg Lozenges
Nicotine

2. Statement of active substance

Each lozenge contains 1.5 mg nicotine (as nicotine resin)

3. List of excipients

Mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, polycarbophil calcium, sodium carbonate, acesulfame potassium, magnesium stearate and flavours.

4. Pharmaceutical form and contents

1 x 20 compressed lozenges
60 (3 x 20) compressed lozenges

5. Method and route of administration

For oromucosal use. Put one Nicabate Mini in your mouth and allow to dissolve fully. For full instructions please read the enclosed leaflet carefully.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach and sight of children.

7. Other special warnings, if necessary**8. Expiry date**

EXP:

9. Special storage conditions

Do not store above 30°C. Store in the original container in order to protect the product from moisture.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal product, if appropriate**11. Name and address of marketing authorisation holder**

To be completed nationally.

12. Marketing authorisation number**13. Batch number**

Lot

14. General classification for supply

To be completed nationally.

15. Instructions for use

Stop smoking aid

Maximum 15 lozenges per day.

16. Information in Braille

Particulars to appear on the Outer Packaging

1. Name of the medicinal product

Nicabate Mini 4 mg Lozenges
Nicotine

2. Statement of active substance

Each lozenge contains 4 mg nicotine (as nicotine resinate)

3. List of excipients

Mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, polycarbophil calcium, sodium carbonate, acesulfame potassium, magnesium stearate and flavours.

4. Pharmaceutical form and contents

1 x 20 compressed lozenges
60 (3 x 20) compressed lozenges

5. Method and route of administration

For oromucosal use. Put one Nicabate Mini in your mouth and allow to dissolve fully. For full instructions please read the enclosed leaflet carefully.

6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach and sight of children.

7. Other special warnings, if necessary

8. Expiry date

EXP:

9. Special storage conditions

Do not store above 30°C. Store in the original container in order to protect the product from moisture.

10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal product, if appropriate

11. Name and address of marketing authorisation holder

To be completed nationally.

12. Marketing authorisation number

To be completed nationally.

13. Batch number

Lot

14. General classification for supply

To be completed nationally.

15. Instructions for use

Stop smoking aid

Nicabate Minis are used to help people stop smoking.

FOR THOSE WHO SMOKE 20 CIGARETTES OR LESS PER DAY

HOW TO USE

Do not use more than 15 Nicabate Minis a day.

Young people (12-17 years inclusive) should only use Nicabate Minis following advice from a healthcare professional.

DO NOT USE

- if you are allergic to any of the ingredients listed.
- if you are a non-smoker or under the age of 12 years.

CONSULT A HEALTHCARE PROFESSIONAL

- if you have or have recently had heart problems
- if you have serious liver or kidney disease; uncontrolled overactive thyroid gland or pheochromocytoma; stomach ulcers or other problems with your stomach or throat.
- before use if you are pregnant or breast feeding.

16. Information in Braille

To be completed nationally.

**Particulars to appear on the Immediate Packaging -
Polypropylene Tube**

1. Name of the medicinal product

Nicabate Mini 4 mg Lozenges
Nicotine

2. Statement of active substance

4 mg nicotine

3. List of excipients

4. Pharmaceutical form and contents

20 lozenges

5. Method and route of administration

Read the package leaflet before use.

Dissolve 1 lozenge fully in mouth over about 10 minutes.

**6. Special warning that the medicinal product must be stored out of
the reach and sight of children**

Keep out of the reach and sight of children.

7. Other special warnings, if necessary

8. Expiry date

EXP:

9. Special storage conditions

Store below 30°C in the original container.

**10. Special precautions for disposal of unused medicinal products or
waste materials derived from such medicinal product, if
appropriate**

11. Name and address of marketing authorisation holder

To be completed nationally.

12. Marketing authorisation number

13. Batch number

Lot

14. General classification for supply

To be completed nationally.

15. Instructions for use

Stop smoking aid

Maximum 15 lozenges per day.

16. Information in Braille

Module 5

Scientific discussion during initial procedure

I INTRODUCTION

Based on the review of the data on quality, safety and efficacy, Austria, Belgium, Germany, Italy, Luxembourg, the Netherlands, Poland, Portugal, Spain and the UK considered that the applications for Nicabate Mini 1.5 and 4mg Compressed Lozenges could be approved. The products are available on General Sales Licences (GSL) for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt. Permanent cessation of tobacco use is the eventual objective. Nicabate Mini 1.5 and 4mg Compressed Lozenges should preferably be used in conjunction with a behavioural support programme.

These are applications made under Article 8.3 of 2001/83 EC, as amended, for a known active substance (nicotine resinate). Nicotine resinate belongs to the pharmacotherapeutic group “drugs used in nicotine dependence” (N07B A01).

Nicotine is a liquid alkaloid obtained from the dried leaves of the tobacco plant, *Nicotiana tabacum* and related species (*Solanaceae*). Tobacco leaves contain 0.5 to 8% of nicotine combined as malate or citrate.

Nicotine is readily absorbed through mucous membranes and the skin; bioavailability of oral nicotine is low due to extensive first pass metabolism. Nicotine is widely distributed; it crosses the blood brain barrier and the placenta and is found in breast milk. The elimination half life is about 1 to 2 hours. Nicotine is metabolised mainly in the liver via the cytochrome P450 isoenzyme CYP2A6 to cotine and nicotine-N-oxide. Nicotine and its metabolites are excreted in the urine.

No new preclinical studies were conducted, which is acceptable given that the product contains a widely-used, well-known active substance. Clinical studies on Nicabate Mini 1.5 and 4.5mg Compressed Lozenges were carried out in accordance with Good Clinical Practice (GCP).

For manufacturing sites outside the community, the RMS has accepted copies of current GMP Certificates or satisfactory inspection summary reports, ‘close-out letters’ or ‘exchange of information’ issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-Community sites.

For manufacturing sites within the community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

At the end of the decentralised procedure, these products were referred to CMD(h) by one member state because of the following issue:

- The addition of “including cravings” in the therapeutic indications of the SPC (Section 4.1) was considered unacceptable as this has not been approved for other similar products and was not supported by clinical data.

This was discussed at Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human, CMD(h), and successfully resolved with the following changes made to the SPC:

- The change of “including cravings” to “including cravings during a quit attempt”
- The addition of “Cravings and other symptoms of nicotine withdrawal are at their most intense during the first few weeks of a quit attempt, diminishing thereafter” and “The lozenges replace some of the nicotine provided by tobacco and clinical studies measuring intensity of cravings and other withdrawal symptoms have been shown to alleviate these symptoms when they are at their most intense” to Section 5.1 of the SPC.

For further details, please see the clinical assessment of this Public Assessment Report.

II. ABOUT THE PRODUCT

Name of the product in the Reference Member State	Nicabate Mini 1.5mg Compressed Lozenges Nicabate Mini 4mg Compressed Lozenges
Name(s) of the active substance(s) (INN)	Nicotine (as nicotine resinate)
Pharmacotherapeutic classification (ATC code)	Drugs used in nicotine dependence" (N07B A01)
Pharmaceutical form and strength(s)	1.5 and 4mg compressed lozenges
Reference numbers for the Decentralised Procedure	UK/H/0287/0013-14/DC
Reference Member State	United Kingdom
Member States concerned	Austria, Belgium, Germany, Spain, Italy, Luxembourg, the Netherlands, Poland, Portugal and Sweden
Marketing Authorisation Number(s)	PL 00079/0612-3
Name and address of the authorisation holder	Beecham Group plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, T/A GlaxoSmithKline Consumer Healthcare, Brentford TW8 9GS, UK.

III SCIENTIFIC OVERVIEW AND DISCUSSION

III.1 QUALITY ASPECTS


S. Active substance

INN/Ph.Eur name: Nicotine (as nicotine resinate)

Chemical name: 2-propenoic acid, 2-methyl, polymer with diethenylbenzene, complex with 1-methyl-2-(3-pyridyl)pyrrolidine.

Methacrylic acid polymer with divinylbenzene, complex with nicotine-S-3-(1-methyl-2-pyrrolidinyl)pyridine.

Structural formula:



Molecular formula: $C_{10}H_{14}N_2 (C_4H_6O_2)_x (C_{10}H_{10})_y$

Appearance: White to faintly yellow powder, practically insoluble in water and insoluble to slightly soluble in most solvents

Molecular weight: $162 + 86(x) + 130(y)$

Chirality: The only chiral centre is at the pyrrole carbon attached to the pyridine.

Nicotine is the subject of a European Pharmacopoeia monograph.

Synthesis of the drug substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents, and these are supported by relevant certificates of analysis.

An appropriate specification is provided for the active substance, with suitable test methods and limits. The methods of testing and limits for residual solvents are in compliance with current guidelines. Batch analysis data are provided and comply with the proposed specification.

Appropriate proof-of-structure data have been supplied for the active pharmaceutical ingredient. All potential known impurities have been identified and characterised. Suitable certificates of analysis have been provided for all reference standards used.

The active substance is packaged in low-density polyethylene bags, which are placed in high-density polyethylene drums and sealed. Specifications for all packaging have been provided. The primary packaging has been shown to comply with current legislation concerning materials in contact with food.

Appropriate stability data have been generated showing the active substance to be a physically and chemically stable drug, and supporting the proposed retest period of 1 year.

P. Medicinal Product

Other Ingredients

Other ingredients consist of pharmaceutical excipients potassium bicarbonate, sodium alginate, mannitol, calcium polycarbophil, sodium carbonate anhydrous, xanthan gum, magnesium stearate, peppermint flavour, taste masking flavour, flavour methanol and acesulfame potassium.

All excipients comply with their European Pharmacopoeia monograph, with the exception of peppermint flavour, taste masking flavour and methanol flavour (which are controlled to a suitable in-house specification) and calcium polycarbophil (USP).

None of the excipients contains materials of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of these products.

Pharmaceutical Development

The objective of the development programme was to formulate new lozenge products (at strengths appropriate to light and heavy smokers) that dissolve faster, are smaller in size and better tasting than the current lozenge products.

The rationale for the type of pharmaceutical form developed and formulation variables evaluated during development have been stated and are satisfactory.

The rationale and function of each excipient added is discussed. Levels of each ingredient are typical for a product of this nature and have been optimised on the basis of results from development studies.

Manufacturing Process

Satisfactory batch formulae have been provided for the manufacture of both strengths of product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results.

Finished Product Specification

The finished product specifications proposed for both strengths are acceptable. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of analysis have been provided for any working standards used.

Container-Closure System

Both strengths of tablets are packaged in child-resistant polypropylene tablet container and cap, incorporating a molecular sieve desiccant (sodium aluminosilicate). Each container contains 20 lozenges. Packs may contain one or three tablet containers.

Satisfactory specifications and certificates of analysis have been provided for all packaging components. All primary packaging complies with the relevant regulations regarding use of materials in contact with food.

Stability of the product

Stability studies were performed on batches of all strengths of finished product in the packaging proposed for marketing and in accordance with current guidelines. These data support a shelf-life of 2 years with the storage conditions “Do not store above 30°C” and “Store in the original package in order to protect the product from moisture”.

Summary of Product Characteristics (SPC), Patient Information Leaflet (PIL), Labels

The SPC, PIL and labelling are pharmaceutically acceptable.

The marketing authorisation holder has stated that they do not wish to market the product in the UK at the current time, but have committed to submitting mock-ups of the PIL and packaging before marketing either product.

The PIL is in compliance with current guidelines and user testing results have been submitted. The results indicate that the PIL is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

MAA forms

The MAA forms are pharmaceutically satisfactory.

Expert report

The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical dossier.

Conclusion

The grant of marketing authorisations is recommended.

III.2 PRE-CLINICAL ASPECTS**1. INTRODUCTION****1.1 Type of application and aspects on development**

These are decentralised applications for Nicabate/Nicotine 1.5 mg and 4 mg Mini Lozenges containing nicotine as the complex nicotine polacrilex (1.5mg and 4mg strengths contain equivalent to 8.333 and 22.222mg nicotine polacrilex, respectively).

The applicant is seeking a line extension to replace nicotine with nicotine polacrilex (with the same therapeutic moiety), to add a new pharmaceutical form, new strength and new route of administration to their currently marketed NiQuitin CQ transdermal patch, which is available in three strengths namely 7, 14 and 21 mg (UK/H/287/01-03; PL 00079/0345-0347). These applications are complete application submitted under Article 8.3 of Directive 2001/83/EC as amended by 2004/27/EC.

The active ingredient in both the originator product and the current application is identical. The compressed lozenges provide similar plasma concentrations of nicotine to the transdermal patch, albeit via different pharmaceutical forms and by different routes of administration. Therefore the applicant has not conducted any further specific pharmacotoxicological studies. The applicant asks that, given that substantial toxicological data on nicotine and its metabolites exist, the reviewer be referred to the NiQuitin CQ patch application for an in depth review and critical assessment of the safety of nicotine. This is acceptable. Since the non-clinical data submitted in support of the application for the originator product has been assessed previously, they will not be reassessed here. In the proposed product, nicotine is formulated as its polacrilex (NPA) salt, because NPA is more stable and easier to formulate than nicotine.

In addition the applicant has provided a review of more recent published toxicological data that have become available in the scientific literature since the submission of the original application. Doses or plasma levels of nicotine presented in the published data have been compared to nicotine exposures or plasma levels resulting from use of the Lozenges at the

recommended dosage. Additionally, a summary of the excipients and a review of the identified degradation products and residual solvents are also presented.

The proposed indication is similar to that approved for the transdermal patch.

The proposed maximum recommended daily dose is 15 lozenges; 22.5mg for the 1.5mg strength or 60mg for the 4mg strength of nicotine. The maximum daily dose approved for the originator product is 21mg of nicotine.

The main non-clinical concerns are whether oromucosal administration of NPA increases systemic exposure (hence toxicity) or causes local irritation or retention of dose in the oromucosal cavity.

1.2 GLP aspects

No new non-clinical studies were submitted in support of this application. Reference is made to published data in the Non-Clinical Overview but the GLP status of these published reports cannot be verified.

2. PHARMACOLOGY

Nicotine is an agonist at both peripheral and central nervous system receptors with a well-established pharmacology, including adrenergic and cholinergic autonomic effects. The pharmacodynamic effects of nicotine have been well-documented in published literature. No new studies of the pharmacodynamic effects of nicotine have been published since submission of the NiQuitin CQ transdermal patch application. It is considered that human data have largely superseded those of animals in relation to the pharmacology of nicotine. Based on the available data and established clinical experience with similar nicotine replacement therapy products, the pharmacological profile of nicotine, when used in a controlled manner is well characterized and hence no further studies have been submitted nor are required.

3. PHARMACOKINETICS

No new non-clinical pharmacokinetic (PK) studies with the proposed lozenge formulations have been performed. Absence of non-clinical PK data with the mini lozenges is considered acceptable; as such data would be superseded by clinical PK data.

Published data indicate that nicotine is rapidly absorbed across the buccal mucosa and GI tract, the amount of nicotine absorbed increases with the increase in pH ($pK_a=8$). The proposed formulations include bicarbonate to increase the pH. Once swallowed, nicotine is poorly absorbed in the acidic gastric environment, and undergoes extensive first pass metabolism. It is reported that after oromucosal administration to humans, the lozenges completely dissolve in the oral cavity within 20-30min. The dissolved nicotine is then absorbed either through the buccal mucosa or ingested and absorbed from the GI mucosa. Apparently, a peak plasma concentration of 9.09 ng/ml nicotine is achieved following a single use of the 4 mg Nicotine Mini Lozenge. When used once every 60 minutes, a peak steady state plasma concentration of 18.4 ng/ml nicotine is achieved with the 1.5 mg Nicotine Mini Lozenge. In comparison, the peak steady state plasma concentrations of nicotine achieved from use of the NiQuitin CQ 14 and 21 mg patch are 16.8 and 23.5 ng/ml, respectively, while the mean steady state concentrations of nicotine are 11.8 and 17.1 ng/ml, respectively. In contrast, half-hourly smoking of cigarettes produces average plasma concentrations of approximately 44 ng/ml (NiQuitin CQ Part IV, Original Clinical Documentation, 1991, Section 3.11.1, Summary of Product Characteristics).

No new scientific literature regarding the absorption, distribution or excretion of nicotine has been reported since submission of the original application. Since similar plasma concentrations are achieved following administration of the mini lozenges in comparison to the original product it is acceptable to cross refer to the pharmaco-toxicological data previously assessed for the NiQuitin CQ Transdermal Patch.

Several new studies on the metabolism of nicotine have been reviewed by the applicant since submission of the original application. These studies investigate the potential of nicotine to activate cytochrome p450 2E1 (CYP2E1), an isoenzyme known to bioactivate tobacco smoke components and other pre-carcinogens. Conclusions drawn from studies are conflicting. In one study, nicotine increased CYP2E1 levels in rats, even at low doses; in another study nicotine was shown to inhibited CYP2E1 activity, with respect to its ability to convert p-nitrophenol to 4-nitrocatechol. Another recent study revealed that CYP2A13-catalyzed 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK - a nicotine-derived carcinogen) metabolism was inhibited competitively by nicotine suggesting that nicotine is a substrate of CYP2A13.

Given the conflicting nature of these findings, The applicant concludes that, along with the fact that the metabolic pathway for nicotine varies with animal species and the fact that the *in vivo* induction of CYP2E1 by nicotine has not been demonstrated to date in humans, the newly reported findings are consider to be of limited relevance to the use of Nicotine Mini 1.5mg and 4mg Lozenges. While the reported results indicate that CYP2A13 can efficiently activate the metabolism of nicotine, the observed *in vitro* results cannot be directly correlated to reactions that occur *in vivo*. Even if CYP2A13 does activate the metabolism of nicotine *in vivo*, CYP2A13 is predominantly expressed in the human respiratory tract and not in the liver, which is the primary site for the metabolism of nicotine. As such, the low level of CYP2A13 expression in the human liver would play an insignificant role in the clearance of nicotine from the human body (Module 2: NiQuitin/Nicotine Mini - Non-Clinical Overview).

From a non-clinical point of view the SPC sections 5.1 and 5.2 are satisfactory.

4. TOXICOLOGY

No new preclinical studies using the proposed formulation are submitted. The applicant briefly summarises the toxicity of nicotine in experimental animals.

4.1 Single dose toxicity

Acute doses of nicotine administered by various routes (iv, sc, oral etc) are relatively toxic with LD₅₀ of generally <100mg/kg in rodents, dogs and rabbits. In mice, rats, rabbits and dogs major toxicological effects of sub-acute and chronic doses of nicotine appear to be cardiovascular and metabolic effects which reflect exaggerated pharmacological activity of nicotine.

Data published in 2000 revealed LD₅₀ values of 57.6 mg/kg for nicotine and 62.1 mg/kg for a tobacco extract containing nicotine following acute administration to male mice.

4.2 Repeat-dose toxicity

Several non-clinical repeat dose toxicity studies have been reported in the literature since the assessment of the non-clinical package for the originator product.

Data published in 1999 indicate that chronic parenteral administration of nicotine (3.0 or 4.5 mg/kg/day) to female rats for 3 months adversely affected bone formation and reduced body storage of vitamin D. A second publication indicates that the mechanism of acute and

chronic effects of nicotine on T-lymphocytes appears to be distinct, in that chronic administration of nicotine causes T cell anergy whereas acute effects are mediated via activation of the hypothalamus-pituitary-adrenal axis. The cardiovascular effects of nicotine in female rats were further investigated in 2001; following subcutaneous administration of 4.5 mg/kg/day of nicotine for 15 to 22 days, there was an effect on nitric oxide's down-regulation of calcium channels and up-regulation of calcium-activated potassium channels, which is required for full vasorelaxation. The same year it was reported that, in rats, nicotine caused a dose-dependent degeneration of axons in the brain (neurotoxicity) following subcutaneous administration of nicotine tartrate over 5 days by continuous infusion or by injection at doses up to 43.1 mg/kg/day and 11.32 mg/kg/day respectively.

In 2003 it was reported that Nicotine caused a reduction in heart weight, heart length and overall blood volume in a dose-related manner following subcutaneous administration of up to 12 mg/kg/day for 14 days. In 2004 the effects of nicotine on lung morphology were investigated in Wistar rats. Following a single intraperitoneal dose of 1 mg/kg for 8 days, an increase in volume fraction of alveolar parenchyma, a reduction of volume and surface fraction of septal elastic fibers, and an increase of the numerical fraction of microvasculature vessels were noted. This indicates progressive morphological damage to lungs caused by nicotine, even after a recovery period.

These studies do not reveal any further toxicity issues than those previously assessed for the originator product and hence do not adversely alter the safety profile of previously approved nicotine replacement therapy products nor highlight further concerns relating to the safety profile of the current proposed products.

4.3 Genotoxicity

No new data are submitted as a range of nicotine concentrations have been previously assessed (NiQuitin CG Transdermal Patch submission) using the standard battery of *in vitro* and *in vivo* genotoxicity tests to reveal that nicotine is not mutagenic in the appropriate assays. However, two additional *in vitro* studies have recently been published in the scientific literature which has revealed potential mutagenic and genotoxic effects of nicotine. In one of these studies exposure to nicotine for 60 minutes at 0.125, 0.25, 0.5, 1, 2, and 4 mM nicotine induced a statistically significant dose-dependent increase of DNA migration up to 3.8-fold and 3.2-fold in DNA sourced from human lymphatic cells of palatine tonsils and human lymphocytes, respectively. DNA migration is used as a measure of possible single strand breaks, alkali labile sites and incomplete repair sites. The lowest observed effect level was 0.5 mM. In the second study, using the *in vitro* cytokinesis-block micronucleus test, the effects of nicotine on DNA damage induction and apoptosis in human fibroblasts was reported. 1 µM of nicotine caused a statistically significant increase in micronucleus frequency, attenuated staurosporine induced apoptosis, and an increase in reactive oxygen species. In contrast, a recent *in vivo* mouse bone marrow assay reported no increase in micronucleus frequency in polychromatic erythrocytes, following single oral doses of 1 or 2 mg/kg.

Assessor's comment

The recent genotoxic effects revealed in the *in vitro* human assays do not support effects seen in the recent *in vivo* micronucleus test nor the previous findings assessed for the originator product. Since the originator product and the proposed product exhibit comparable similar systemic exposure, it can be assumed that the genotoxic potential of the mini lozenges will also be similar.

4.4 Carcinogenicity

Review of literature in the Niquitin CQ patch applications suggests that nicotine, cotinine and nicotine N-oxides are not carcinogenic, but some studies have reported a co-carcinogenic effect for nicotine and nicotine N-oxides. Repeat application of nicotine (for 12 weeks) in combination with 7,12-dimethylbenzanthracene (DMBA) to the cheek pouch mucosa of hamsters increased the incidence of tumours induced by DMBA, while no tumours were seen when nicotine alone was applied. In addition, nicotine also enhanced the carcinogenic effects of N-nitrosornicotine (NNN) and 4-(N-methyl-N-nitrosamine)-1-(3-pyridyl)-1-butanone (NNK) following repeated application to the cheek pouch mucosa of hamsters. These co-carcinogenic effects of nicotine are not considered relevant because under normal circumstances patients taking the mini lozenges would not be exposed to such potential carcinogens.

Other components of tobacco smoke such as nitrosamines and polycyclic aromatic hydrocarbons are potentially carcinogenic. The use of nicotine-containing lozenges would provide a lower risk in comparison with smoking, given the absence of carcinogenic components of tobacco smoke.

4.4.1 Tumourigenic Potential

A potential link between nicotine exposure and enhanced tumour growth was first reported in 2001 following *in vitro* studies using human endothelial cells and *in vivo* studies in mice. Results revealed increased growth of the human cells, increase in the formation of cellular networks and decreased apoptosis under hypoxic conditions. In mice, nicotine increased capillary formation and vascularization, accelerated atherosclerotic lesion growth and enhanced tumour growth, but not tumour proliferation. Enhanced tumour neovascularization and growth has been reported in mice administered 20 mg/kg/day nicotine for 5 days followed by subcutaneous administration of synergic colon cancer cells. It has also been reported that bone marrow derived cells can contribute to tumour neovascularization in nicotine treated mice. A further experiment revealed that nicotine stimulated vascular endothelial cell growth factor production by the CMT93 (carcinoma cells) but did not stimulate the proliferation of this cell line *in vitro*. In 2004 a study was reported that showing that, *in vitro*, a human adenocarcinoma cell line incubated with 10, 100 or 1000 nM of nicotine exhibited increased cell proliferation in a dose dependent manner. EGFR tyrosine kinase inhibitor (AG1478) and c-Src inhibitor (PP2) phosphorylation and 5-LIPOX protein expression levels were also increased. AG1478 and PP2 alleviated the actions of nicotine on cell proliferation and 5-LIPOX protein expression, and the combination of both agents produced an additive effect. Following the incubation of these cells with nicotine for 5 hours they were injected into the skin of female BALB/c nu/nu mice, a nude mouse xenograft model. Enhanced tumour growth and vascularization was observed in treated mice. Mitogen-activated protein kinase inhibitors were shown to inhibit the nicotine-induced tumour growth and neovascularization seen in nude mice (with gastric cancer cells implanted into the gastric wall) treated with 0, 50, or 200 µg/ml nicotine.

4.4.2 Tobacco-Specific Nitrosamines (TNSA)

An alternate metabolic pathway involving the 2'-hydroxylation of nicotine that results in the *in vitro* formation of a tobacco-specific lung carcinogen precursor has been the subject of a number of scientific studies. In contrast, *in vivo* one study has demonstrated no evidence for the endogenous formation of TNSAs in human subjects who did or did not use 15 mg nicotine patch therapy for 6 weeks following smoking cessation.

Assessor's comment

As summarised above; the clinical relevance of this data on the tumourigenic potential of nicotine in humans is unknown; however, it has to be born in mind that nicotine replacement therapy is preferable to tobacco smoke.

The ability of nicotine to facilitate the formation of TNSAs is inconclusive as the *in vitro* formation of TNSAs was not seen *in vivo*. Any non-clinical findings would be superceded by the findings in the human study, which did not reveal the presence of endogenous TNSAs following treatment with nicotine alone.

4.5 Reproductive and developmental toxicity

The applicant cross-refers to data submitted in the Niquitin CQ patch dossiers. Literature published since the Niquitin CQ Patch applications report the following findings:

- In male rats, nicotine (4mg/kg, oral or ip) reduced epididymis and vas deferens weights and sperm count and produced abnormal sperm morphology.
- In female rats, nicotine (3mg/kg, oral or ip) decreased ovarian and uterine weights.
- Perinatal exposure to nicotine (sc, 6mg/kg/day) impaired ability of new-born rats to autoresuscitate from primary apnoea during repeated exposure to hypoxia.
- In female mice, nicotine (5, 7.5 or 10mg/kg) did not significantly perturb the rate of oocyte maturation or increase the frequency of aneuploidy.
- In female rats, nicotine (6.0 mg/kg/day (day 4 – 20 of gestation)) increased the density of serotonin transporter binding sites in the forebrain of their offspring, which could adversely affect physiological / behavioural development.
- In rats, nicotine (9.0 mg/kg/day - 23 days from day 4 of gestation) increased the binding of [¹²⁵I]epibatidine, which labels $\alpha 4\beta 2$ nicotinic receptors, in layer 1 of the visual cerebral cortex and layer 1 of the somatosensory cerebral cortex of their offspring. Again resultant adverse behavioural development could be expected
- Prenatal exposure to nicotine (2.0 mg/kg/day - throughout gestation) caused a decrease in cell size, cell layer thickness, and cell packing density of neurons in the hippocampus and dentate gyrus in rats offspring. Indicative of abnormal neuronal maturation leading to alteration in the structure of key brain regions responsible for learning, memory and cognition.
- Prenatal exposure to nicotine (3.0 to 5.0 mg/kg/day nicotine from day 7 of gestation to postnatal day 32) significantly retarded development and decreased the maximum density of presynaptic high affinity-choline transport sites and selectively reduced postsynaptic muscarinic receptor density in the cerebral cortex of, suggesting inhibition in the development of cholinergic pathways both pre- and post-synaptically.

An abstract published in 1998 reported that sc administration of nicotine (0.35, 1.1 or 3.5mg/kg/day) alone or in combination with mecamylamine to rats (GD 6-15) and rabbits (GD 6-18) caused maternal toxicity in both species and developmental effects (lower foetal weights and retarded ossification) in rats only.

Pre- and postnatal exposure to nicotine has been shown to adversely affect the development of the gas exchange region in lungs. Observations include suppression of alveolarisation, reduction in internal lung surface area and lower radial alveolar counts and number of capillaries in the septa in rat offspring. A range of studies report findings that indicate prenatal nicotine exposure impairs protective responses that may sustain life during exposure to hypoxia in an age-dependent manner.

Adverse behavioural affects (hyperactivity) have been revealed following sc administration of nicotine (0.75 – 3.0 mg/kg/day) to rats from day 4 of gestation through to postnatal day 16.

Studies in juvenile animals indicate that nicotine causes hypoactivity at 4 months in mice previously administered nicotine on postnatal days 10 to 14. These findings indicate a time-response / time0dependent effect.

The applicant considers these effects of nicotine to be of little relevance to the intended use of nicotine lozenges, considering the doses and routes of administration used (effects mainly seen following ip. administration) and that fact that similar findings have been previously presented in the NiQuitin CQ transdermal patch application.

4.6 Local tolerance

No preclinical local tolerance studies with the nicotine mini lozenges have been performed and the applicant asks that the reviewer be referred to the pharmaco-toxicological documentation summary assessed for the NiQuitin CQ transdermal patch application. Immortalised hamster cheek pouch cells *in vitro* and hamster cheek pouch tissue *in vivo* was subjected to incubation/treatment with nicotine and other smokeless tobacco extracts. *In vitro* nicotine induced DNA strand breaks and a dose-dependent decrease in viability of the cheek pouch cells; *in vivo* nicotine induced mild epithelial dysplasia following 10 months of treatment (three times a week). Alterations in ligand-binding kinetics of nicotinic acetylcholine receptors (which can affect oral tissues) was observed in rats and mice following oral administration of nicotine for 3 weeks. However, it has been reported that nicotine 2mg sublingual tablets (up to 20-40 tablets daily, for up to 6 months) caused no adverse long-term effects on the oral mucosa of humans and any lesions that did occur were transient and reversible. Similar findings are reported in a preclinical *in vivo* study, whereby hamster oromucosa treated with nicotine for 12 weeks exhibited no adverse effects.

Assessor's comment

Adverse effects were reported *in vitro*, however, distinctly different findings are reported *in vivo* and in the clinic. It is anticipated that the proposed lozenges will not cause any local irritation at the MRD of 15 lozenges per day. Extensive clinical use with Nicotine Replacement Therapy (NRT) Lozenges supports this.

4.7 Other toxicity studies

4.7.1 Components of Lozenges

Inactive ingredients of these lozenges include polacrilex resin to which nicotine is bound, mannitol, sodium alginate, xantham gum, potassium bicarbonate, calcium polycarbophil, sodium carbonate, acesulfame-K, magnesium stearate, and the mint powder flavouring. With the exception of the flavours, all of the inactive ingredients are approved pharmaceutical grade materials (European Pharmacopoeia, United States Pharmacopoeia and/or United States National Formulary) and hence no preclinical data has been submitted in support of their use.

The proposed maximum daily intake (MDI) of mannitol is 2.5g. An acceptable daily intake(ADI) of mannitol has not been specified by the WHO since the amount consumed as a sweetening agent was not considered to represent a hazard to health .however, it has been reported that laxative effects may occur if orally consumed in large quantities (approximately 20g daily). The proposed MDI of calcium polycarbophil is 76mg. Again an acceptable daily intake for calcium polycarbophil has not been specified by the WHO. However it has been reported that daily dosages of up to 4 to 5 g in adults appears to be quite safe and non-toxic. The proposed MDI of sodium (as sodium carbonate and sodium alginate) is approximately 279mg. In the UK, dietary reference values have been published that recommend sodium intake be limited to 1.6g daily. The WHO has specified an ADI of 15mg/kg for acesulfame-K and the proposed MDI is 0.45mg/kg for a 50kg person.

Magnesium stearate is a widely used non-toxic component of solid dosage formulations between 0.25% and 5.0% w/w. potassium bicarbonate acts as the buffering agent

The components of the flavouring agents are designated as substances that are generally recognised as safe (GRAS). Additionally, each of these flavours complies with the provisions of EEC Directive 88/388/EEC. Exposure to each of these inactive ingredients from use of Nicotine/Nicabate 1.5 mg and 4 mg Mini Lozenges is comparable to exposures from similar products that are currently marketed.

There are no apparent safety concerns with respect to the proposed components of the mini lozenges as all comply with the published acceptable daily intake levels, where applicable, or appropriate guidance.

4.7.2 Degradation Products

Potential degradation products/impurities of nicotine polacrilex are cotinine, nicotine N-oxides, [(1'R,2'S)-nicotine-1'-N-oxide and (1'S,2'S)-nicotine-1'-N-oxide, myosmine, a complex of nornicotine and anatabine, and pseudooxynicotine.

These impurities are controlled according to USP. Given the proposed MDI of 60mg nicotine; ICH Q3B(R2) - *Impurities in New Drug Products*; specifies that the reporting, identification and qualification thresholds are 0.1%, 0.2% and 0.5% (or 200µg total daily intake, which ever is lower) respectively. The FPS limits proposed for named impurities are, therefore, above the lower ICH threshold for qualification. However, the proposed limits for cotinine and the N-oxides are considered acceptable given that are potential metabolites of nicotine. The set limit for myosmine is also deemed acceptable since it is a naturally occurring alkaloid less toxic and less pharmacologically potent than nicotine.

The limits set for Pseudooxynicotine and the Nornicotine/ Anatabine complex could result in a total daily intake of 300µg. Results of stability analyses have revealed that Nornicotine/ Anatabine complex consists of 78.9 to 87.8% nornicotine and 12.2 to 21.1% anatabine. Therefore each component of the complex can be calculated to be up to 263.4 µg/day (5.3 µg/kg/day; 0.439%) nornicotine and up to 63.3 µg/day (1.3 µg/kg/day; 0.106%) anatabine. To justify the limits of nornicotine and Pseudooxynicotine, the applicant has reviewed and presented relevant toxicological publications in scientific literature.

Nornicotine has been revealed as a metabolite of nicotine in several animal species and humans, with and LD₅₀ value approximately 566-fold more than the proposed MDI, and minor mutagenic potential at high concentrations (2.5mg/ml).

Pseudooxynicotine has been identified as a mixture of four molecular species in equilibrium, consisting of 2'-hydroxynicotine, nicotine-1',2'-iminium ion, N-methylmyosmine and pseudooxynicotine (aminoketone). A structure-activity relationship (SAR) analysis was performed for each of the four molecular species that comprise the pseudooxynicotine complex using DEREK (Deductive Estimation of Risk from Existing Knowledge) version 6.0.0. DEREK is a rule based application, which compares the compound of interest with the substructural features contained within its knowledgebase that are indicators for mutagenicity, carcinogenicity, sensitization, irritation and other toxicological endpoints, including developmental toxicity, teratogenicity, nephrotoxicity, hepatotoxicity, neurotoxicity, pulmonary toxicity and estrogenicity. This evaluation resulted in no alerts for 2'-hydroxynicotine, nicotine-1',2'-iminium ion, or N-methylmyosmine. However, an alert resulted for pseudooxynicotine, because as an aminoketone it is a secondary amine and under the appropriate conditions has the potential to be nitrosated to form nitrosamine, 4-

(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Once activated, NNK is said to be a significant initiator of lung cancer, since it induces benign and malignant lung tumours in rodents. Human lung tissue can activate NNK. NNK has been shown to produce pancreatic cancer in rats and metaplasia in human pancreatic explants. Its carcinogenic potential has also been demonstrated in the nasal cavity and liver of rodents.

The applicant concludes that since alternate metabolic pathways exist for secondary amines, that the nitrosation of this amine in the stomach requires optimal chemical conditions, and that there is a lack of a concomitant source of nitrate or nitrite in the proposed product, nitrosation of the minimal amount of pseudooxynicotine to form the nitrosamine NNK is considered highly unlikely. The applicant continues with the predication that use of Nicotine 1.5 mg and 4 mg Mini Lozenges for a prescribed period of around 6 weeks, depending on the patient, would result in a significantly lower exposure to pseudooxynicotine than exposures associated with chronic smoking. Exposure to tobacco-specific nitrosamines, including NNK, has also been definitively shown to occur from cigarette smoking, while to date the endogenous formation of tobacco-specific nitrosamines has not been demonstrated to occur *in vivo* from use of nicotine replacement therapies.

In view of the above justifications, and the fact that the, the proposed limits for Pseudooxynicotine and the Normicotine/ Anatabine complex have previously been approved for products already marketed in Europe (NiQuitin CQ 2mg, 4mg Mint Lozenges – PL 00079/0373-4– approved in UK 2002; UK/H/287/11-12), the proposed finished product shelf life specification limits for the impurities are acceptable.

The limits proposed for residual solvents, namely cyclohexane, dichloromethane, 2-propanol and acetic acid, comply with ICH Q3C(R3) *Impurities: Residual Solvents*.

4.8 Ecotoxicity/environmental risk assessment

This is an application for a line extension product and there is no reason to conclude that marketing of this product will change the overall use pattern of the existing market.

4.9 Assessor's overall conclusions on toxicology

No new preclinical data were supplied with this application, which is justified by the fact that exposure to the active ingredient (nicotine) is not likely to be significantly greater following administration of the proposed formulation compared to the originator product. Therefore, clinical experience with nicotine overrides the need for further preclinical data. The nonclinical overview provides a satisfactory review of the relevant preclinical pharmacological and toxicological literature published since approval of the originator product. The degradation products are considered toxicologically qualified or meet ICH guidelines. There are no new safety concerns associated with the proposed products.

III.3 CLINICAL ASPECTS

1. Introduction

This assessment report represents an evaluation of the key elements of the information provided by the company in the dossier. For more details, the reader should refer to the company's clinical overview and summary and to the clinical file.

The clinical overview has been written by an appropriately qualified physician. The clinical overview on the clinical pharmacology, efficacy and safety is adequate.

2. Clinical study reports

To support the application, the applicant has submitted four bioequivalence studies.

2.1 *Biowaiver*
Not applicable.

2.2 *Pharmacokinetic studies*
To support the application, the applicant has submitted four bioequivalence studies: three single-centre, three-period, single-dose crossover trials; and a single-centre, single-blind, multiple-dose, crossover design trial.

Study 1: S2300319

Randomised, three-period, single dose, cross-over, bioequivalence study comparing two formulations of test 2mg nicotine polacrilex lozenges versus reference nicotine polacrilex gum.

Study protocol

20 healthy >5/day smokers, 15 male and 5 female, aged 19-55 years, were included in this study. Three subjects discontinued prematurely. Each subject received a 2mg nicotine dose of one of three nicotine formulations. A randomisation scheme was included in the report. The following formulations were administered:

Treatment A: 2mg Nicotine Polacrilex (mannitol based) mini lozenge (GSK. Batch No.: GSK5339B011)

Treatment B: 2mg Nicotine Polacrilex (master mannitol granulation based) mini lozenge (GSK. Batch No.: GSK5337B011)

Reference C: 2mg Nicotine Polacrilex Gum (Nicorette UK. Batch No.: FF085A)

The reference product is registered in UK. The formulations were given following a controlled period of fasting and exclusion from any nicotine intake from 24 hours pre dose. Subjects were free to drink water from 1-hour post dose and eat standard meals from 2 hours. Blood samples were taken at pre-dose and at 5, 10, 15, 20, 30, 45, 50 minutes and at 1, 1.5, 2, 3, 4, 6, 8 and 12 hours after administration of the products. There then followed a 48-hour washout period before crossover and repeat.

The plasma nicotine concentrations were measured by LC/MS/MS. The LLOQ for nicotine was 1ng/ml. $AUC_{(0-t)}$, $AUC_{(0-inf)}$, C_{max} , t_{max} and $t_{1/2}$ were calculated according normal standard procedures.

Statistical evaluation was performed for $AUC_{(0-t)}$, AUC_{inf} and C_{max} with ANOVA and the 90% confidence intervals for the ratio of test formulation over the reference formulation were calculated with the results as follows:

Study Treatment	Mean \pm SD (N)		Mean Ratio #	90% CI #
	2mg Nicotine Polacrilex (mannitol-based) Mini Lozenge	2mg Nicotine Polacrilex Gum		
C_{max} (ng/mL)	4.46 \pm 1.34(18)	3.67 \pm 0.96(19)	121.1	(107.8, 136.0)
$AUC_{(0-t)}$ (ng*hr/mL)	12.13 \pm 4.23(18)	8.102 \pm 2.57(19)	155.0	(136.0, 176.6)
$AUC_{(0-inf)}$ (ng*hr/mL)	16.42 \pm 4.90(16)	12.04 \pm 2.98 (16)	137.9	(123.9, 153.4)
Study Treatment	Mean \pm SD (N)		Mean Ratio #	90% CI #
	2mg Nicotine Polacrilex (MMG-based) Mini Lozenge	2mg Nicotine Polacrilex Gum		
C_{max} (ng/mL)	4.96 \pm 1.70(17)	3.67 \pm 0.96(19)	134.9	(119.7, 152.1)
$AUC_{(0-t)}$ (ng*hr/mL)	13.63 \pm 5.52 (17)	8.102 \pm 2.57(19)	172.7	(150.9, 197.5)
$AUC_{(0-inf)}$ (ng*hr/mL)	17.68 \pm 6.33 (15)	12.04 \pm 2.98(16)	143.1	(127.9, 160.1)

SD= standard deviation
CI = confidence interval
= Based on the least square means
Source: Tables 9.2.2.1, 9.2.2.2, 9.2.2.3, 9.2.3.1, and 9.2.3.2

Three subjects discontinued prematurely and were excluded from analysis. Two subjects discontinued for personal reasons, and one for non-compliance. There were no serious adverse events recorded.

Study 3 S2300320

Randomised, two-period, single-dose, crossover, bioequivalence study comparing the test 4mg nicotine polacrilex lozenges versus reference 4mg nicotine polacrilex gum.

Study protocol

30 healthy >15/day smokers, 21 male and 9 female, aged 19-55 years, were included in this study. Five subjects discontinued prematurely. Each subject received a 4mg nicotine dose of one of two nicotine formulations. The following formulations were administered:

Treatment A: 4mg Nicotine Polacrilex (master mannitol granulation based) mini lozenge (GSK. Batch No.: GSK5336B011)

Reference B: 4mg Nicotine Polacrilex Gum (Nicorette UK. Batch No.: FF022A)

The reference is registered in UK. The formulations were given following a controlled period of fasting and exclusion from any nicotine intake from 24 hours pre dose. Subjects were free to drink water from 1-hour post-dose and eat standard meals from 2 hours. Blood samples were taken at pre-dose and at 5, 10, 15, 20, 30, 45, 50 minutes and at 1, 1.5, 2, 3, 4, 6, 8 and 12 hours after administration of the products. There then followed a 48 hour washout period before crossover and repeat.

The method of plasma analysis was LC-MS/MS. The LLOQ for nicotine was 1ng/ml. $AUC_{(0-t)}$, $AUC_{(0-inf)}$, C_{max} , t_{max} and $t_{1/2}$ were calculated according normal standard procedures.

Statistical evaluation was performed for $AUC_{(0-t)}$, AUC_{inf} and C_{max} with ANOVA and the 90% confidence intervals for the ratio of test formulation over the reference formulation were calculated.

Parameter	Mean \pm SD (N)		% Mean Ratio [#]	90% CI [#]
	4mg Nicotine Polacrilex Mini Lozenge	4mg Nicotine Polacrilex Gum		
C _{max} (ng/mL)	9.09 \pm 2.83 (29)	7.46 \pm 2.33 (26)	--	--
AUC _(0-t) (ng.hr/mL)	33.79 \pm 16.54 (29)	23.91 \pm 12.54 (26)	--	--
AUC _(0-inf) (ng.hr/mL)	39.65 \pm 19.39 (28)	28.69 \pm 13.58 (25)	--	--
ln(C _{max})	2.163 \pm 0.300 (29)	1.961 \pm 0.326 (26)	123.4	(112.2, 135.6)
ln[AUC _(0-t)]	3.430 \pm 0.413 (29)	3.057 \pm 0.489 (26)	149.8	(135.9, 165.1)
ln[AUC _(0-inf)]	3.598 \pm 0.385 (28)	3.264 \pm 0.428 (25)	143.5	(132.6, 155.2)

= Based on the LSMEAN values
Source: Tables 9.2.2.1, 9.2.2.2 and 9.2.3.1

Five subjects discontinued and were excluded from analysis. Two discontinued for personal reasons, one failed drug/alcohol screening, one took prescription medication and one failed to return for period 2. There were no serious adverse events recorded.

Study 4 S2300339

Randomised, two-period, multiple-dose, crossover, bioequivalence study comparing the test 1.5mg nicotine polacrilex lozenges versus reference 2mg nicotine polacrilex gum.

Study protocol

40 healthy >5/day smokers, 30 male and 14 female, aged 19-55 years, were included in this study. Six subjects discontinued prematurely. Each subject received a nicotine dose of one of two nicotine formulations. Each subject received one dose every hour for 13 hours. The following formulations were administered:

Treatment A: 1.5mg Nicotine Polacrilex (master mannitol granulation based) mini lozenge (GSK. Batch No.: GSK5336B013)

Reference B: 2mg Nicotine Polacrilex Gum (Nicorette UK. Batch No.: FF085A)

The reference is registered in UK. The formulations were given following a controlled period of fasting and exclusion from any nicotine intake from 24 hours pre dose. Blood samples were taken at pre-dose and immediately before the 11th, 12th, and 13th doses and following the 13th dose every 10 minutes for 60 minutes. There then followed a 48-hour washout period before cross over and repeat.

The method of plasma analysis was LC-MS/MS and the LLOQ for nicotine was 1ng/ml. A validation report is provided. AUC_(0-t), AUC_(0-inf), C_{max}, t_{max} and t_{1/2} were calculated according normal standard procedures.

Statistical evaluation was performed for AUC_(0-t), AUC_{inf} and C_{max} with ANOVA and the 90% confidence intervals for the ratio of test formulation over the reference formulation were calculated.

Variables	Mean ± SD (N)		Mean Ratio #	90% CI #
	1.5mg Nicotine Polacrilex Mini Lozenge	2mg Nicotine Polacrilex Gum		
AUC _(0-t) (ng*hr/mL)	16.65 ± 6.28 (41)	13.71 ± 3.14 (40)	116.9	(106.7 - 128.1)
C _{max} (ng/mL)	18.40 ± 6.81 (42)	15.33 ± 4.23 (40)	118.5	(107.2 - 131.0)
C _{min} (ng/mL)	15.03 ± 5.55 (42)	12.76 ± 3.10 (38)	114.1	(104.7 - 124.4)
Fluctuation	0.196 ± 0.134 (41)	0.195 ± 0.165 (38)		

SD= standard deviation
CI = confidence interval
= Based on the least square means
Source: Tables 9.2.2.1 , 9.2.2.2 and 9.2.3.1

The following subjects were discontinued from the study:

Reason for Discontinuation	Subject	Treatment Sequence	Party Initiating Discontinuation	Period of Withdrawal
Failed Drug/Alcohol Screen ¹	1010	BA	Investigator	Day 1, Period 2
Personal Reason	1017	AB	Subject	Day -1, Period 2
Other ²	1025	BA	Subject	Day 2, Period 1
Other ²	1030	AB	Subject	Day 2, Period 1
Noncompliance	1032	AB	Investigator	Day 1, Period 2
Personal Reason	1044	AB	Subject	Day -1, Period 2

¹Subject 1010 tested positive for amphetamines
Treatment A = 1.5 mg nicotine polacrilex mini lozenge
Treatment B = 2 mg nicotine polacrilex gum
²Withdrew Consent
Source: Data Listing 2.9.2 and Table 9.1.1

There were no serious adverse events recorded.

Given the suprabioavailability of proposed lozenges, it is considered likely that they will display no less efficacy in the requested indications than that of the reference medicinal product. There would not appear to be any additional safety signals raised from the new 4mg strength.

Additional Information as of Day 160:

Further to the data contained within the original file, the applicant also provides a 4th bioavailability study comparing the proposed 4mg lozenge with their existing 4mg lozenge:

Study 4 S3010466

Randomised, two-period, multiple-dose, crossover, bioequivalence study comparing the test 4mg nicotine mini lozenges versus reference 4mg nicotine lozenge.

Study protocol

28 healthy smokers (defined as requiring a cigarette within 30 minutes of waking), 19 male and 9 female, aged 20-51 years, were included in this study. 27 completed at least one study treatment and 24 completed both. Four subjects withdrew consent from the study. Each subject received a single dose of one of the two nicotine formulations. The following formulations were administered:

Treatment A: 4mg Nicotine mini lozenge (GSK. Batch No.: GSK5526B011)

Reference B: 4mg Nicotine Polacrilex Lozenge (GSK. Batch No.: GSK5498B021)

The reference is registered in UK. The formulations were given following a controlled period of fasting and exclusion from any nicotine intake from 24 hours pre dose. Blood samples were taken at pre-dose and at 5, 10, 15, 20, 30, 40, 50 minutes and at 1, 1.5, 2, 3, 4, 6, 8, 9, 10 and 12 hours following dose administration. There then followed a 48 hour washout period before cross over and repeat.

The method of plasma analysis was LC-MS/MS and the LLOQ for nicotine was 1ng/ml. A validation report is provided. $AUC_{(0-t)}$, $AUC_{(0-inf)}$, C_{max} , t_{max} and $t_{1/2}$ were calculated according normal standard procedures.

Statistical evaluation was performed for $AUC_{(0-t)}$, AUC_{inf} and C_{max} with ANOVA and the 90% confidence intervals for the ratio of test formulation over the reference formulation were calculated.

Table 1: Summary of Baseline-Adjusted Nicotine Pharmacokinetic Variables

Parameter	Means*		Ratio: Mini/Standard	
	Mini	Standard	Estimate	90% CI
C_{max} (ng/mL)	7.23	7.61	95.0%	[87.4%,103.3%]
$AUC_{(0-t)}$ (ng*hr/mL)	24.39	25.63	95.2%	[89.8%,100.9%]

*Geometric adjusted means calculated by exponentiating adjusted mean log

There were no serious adverse events recorded.

The 4mg test and reference lozenges can be considered bioequivalent.

The findings of this study can be extrapolated to lower dose formulations given that the product fulfils the criteria for dose proportionality for immediate release oral dosage forms identified in Section 5.4 of the relevant EU guidelines [CPMP/EWP/QWP/1401/98]:

- The pharmaceutical products are manufactured by the same manufacturer and process.
- The drug input is linear over the therapeutic dose range.
- The qualitative composition of the two strengths is the same.
- The ratio between amounts of excipients is similar for the two strengths.
- The dissolution profiles are similar for both strengths of lozenge.

It is normally considered that the highest dose strength is the most discriminatory for the purposes of bioequivalence testing, which is the strength which has been tested here. The confidence intervals for the bioequivalence parameters of the presented studies are within the required limits by a substantial margin. The results of study S3010466 with the 4mg formulation can be extrapolated to other strength 1.5mg,

according to conditions in Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98, section 5.4.)

The SPC wording is considered to be acceptable in order to address the potential confusion for patients in altering NRT dosage forms.

3. Post marketing experience

Nicotine has a well-recognised efficacy and an acceptable level of safety in the indications approved for Nicabate Mini Lozenges, and corresponding products have been widely used in many countries. Therefore, the submission of PSUR at the renewal of the marketing authorisation is supported.

4. Benefit-Risk assessment

The benefit–risk assessment for this product is considered to be positive, assuming satisfactory answers are provided to the points raised below.

5. Conclusions

During the decentralised procedure, one member state raised the following issue:

- The addition of “including cravings” in the therapeutic indications of the SPC (Section 4.1) was considered unacceptable as this has not been approved for other similar products and was not supported by clinical data.

This was discussed by CMD(h) and the final advice is provided on the next page.

**Final Day 60 position following CMD(h)
Oral Explanation at EMEA on 28 May 2008 for
UK/H/287/013-014/DC**

Final position following CMD(h) Written Explanation

Further to the CMD(h) consideration of the applicant's response to the list of questions and following the oral explanation on 28 May 2008, a positive conclusion has been reached in the procedure with the following comment:

- The procedure is finalised with the Summary of Product Characteristics amended to include the following statement in Section 4.1:
Nicabate Minis are to be used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt (See Section 5.1). Permanent cessation of tobacco use is the eventual objective.

Section 5.1 is amended to include the following:

Nicotine is an agonist at nicotine receptors in the peripheral and central nervous system and has pronounced CNS and cardiovascular effects. When consumed in tobacco products, it has been shown to be addictive and abstinence is linked to craving and withdrawal symptoms. These craving and withdrawal symptoms include urge to smoke, depressed mood, insomnia, irritability, frustration or anger, anxiety, difficulty in concentrating, restlessness and increased appetite or weight gain. Cravings and other symptoms of nicotine withdrawal are at their most intense during the first few weeks of a quit attempt, diminishing thereafter. The lozenges replace some of the nicotine provided by tobacco and clinical studies measuring intensity of cravings and other withdrawal symptoms have been shown to alleviate these symptoms when they are at their most intense.

Member States are requested to recognise the UK Marketing Authorisations and to approve marketing authorisations within 30 days of receipt of suitable translations of the product particulars.

IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT QUALITY

The important quality characteristics of Nicabate Mini 1.5 and 4mg Compressed Lozenges are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

PRECLINICAL

No new preclinical data were submitted and none are required for applications of this type.

EFFICACY

The three comparative biopharmaceutical studies comparing the proposed product versus gum have confirmed that the test products are more bioavailable than the reference gum.

The bioequivalence study comparing the proposed test 4mg lozenge versus an already licensed 4mg lozenge showed that these products can be considered bioequivalent. As these products meet all the criteria as specified in the Note for Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study on the 4mg lozenge can be extrapolated to the 1.5mg lozenge.

No new or unexpected safety concerns arise from these applications.

The SPC, PIL and labelling are satisfactory and consistent with that for other similar products.

RISK-BENEFIT ASSESSMENT

The quality of the product is acceptable and no new preclinical or clinical safety concerns have been identified. Extensive clinical experience with nicotine is considered to have demonstrated the therapeutic value of the compound. The risk benefit is, therefore, considered to be positive.

Module 5

STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY

Date submitted	Application type	Scope	Outcome